Pfirrmann, M
Baccarani, M
Saussele, S
Guilhot, J
Cervantes, F
Ossenkoppele, G
Hoffmann, V S
Castagnetti, F
Hasford, J
Hehlmann, R
Simonsson, B
Article History
Received: 2 September 2015
Accepted: 14 September 2015
First Online: 29 September 2015
Competing interests
: MP acted as a consultant for and received honoraria from Novartis and Bristol-Myers Squibb. MB served on the speakers’ bureau of and received honoraria from ARIAD, Bristol-Myers Squibb, Novartis and Pfizer and acted as a consultant for ARIAD and Novartis. SS acted as a consultant for Novartis, and Pfizer, received honoraria ARIAD, Bristol-Myers Squibb, Novartis and Pfizer, and received research funding from Bristol-Myers Squibb and Novartis. FC served on the speakers’ bureau of and received honoraria from ARIAD, Bristol-Myers Squibb and Novartis and acted as a consultant for ARIAD and Pfizer. GO acted as a consultant for ARIAD, Bristol-Myers Squibb, Celgene, Johnson & Johnson, Novartis and Roche and received research funding from Celgene and Novartis. VSH received research funding from Novartis. F Castagnetti acted as a consultant for and received honoraria from ARIAD, Bristol-Myers Squibb, Novartis and Pfizer. JH received honoraria from Bristol-Myers Squibb and research funding from Novartis; RH received research funding from Bristol-Myers Squibb and Novartis. BS acted as a consultant for and received honoraria from Novartis and Bristol-Myers Squibb.